If you work in oncology or infusion, you already know that biosimilars aren't coming; they're here. For most drugs, your team has figured out the clinical piece. You know the science, you understand interchangeability, and you've read the FDA approvals.

The part that keeps tripping people up isn't clinical. It's communication.

And like I said at the Health Connect Partners event in May (to a room full of chuckles), formulary excites me. 😀 If you don’t believe me, here’s proof...

We're Having a "Make It Make Sense" Moment.